Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Cancers|September 10, 2021
Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side EffectsSophie Beaumont, Simon Harrison, Jeremy ErJournal of Paediatrics and Child Health|October 16, 2014
Paediatric bacteraemias in tropical AustraliaJeremy Er, Peter Wallis, Samuel Maloney, et al.Journal of Biomedical Science|November 16, 2010
Identification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a binding protein for a 68-kDa Bacillus thuringiensis parasporal protein cytotoxic against leukaemic cellsKanakeswary Krishnan, Jeremy Er An Ker, Shar Mariam Mohammed, et al.Internal Medicine Journal|February 25, 2021
Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experienceJeremy Er, David Routledge, Jennifer Hempton, et al.Clinical Lymphoma, Myeloma & Leukemia|July 8, 2025
Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell DyscrasiasMary Sartor, Thomas X Lemarchand, Luise Britz, et al.Advances in Therapy|February 2, 2026
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect ComparisonNieves Lopez-Muñoz, Noffar Bar, Joris Diels, et al.Current Medical Research and Opinion|August 12, 2024
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparisonNoffar Bar, Joris Diels, Suzy van Sanden, et al.Blood|July 11, 2025
Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomicsRaymond K H Yip, Jeremy Er, Lei Qin, et al.Nature Communications|October 22, 2024
In situ visualization of endothelial cell-derived extracellular vesicle formation in steady state and malignant conditionsGeorgia K Atkin-Smith, Jascinta P Santavanond, Amanda Light, et al.The New England Journal of Medicine|February 12, 2025
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J Harrison, Cyrille Touzeau, Nicolas Kint, et al.Pageof 2